Atherosclerosis Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2027

Jan 2020| FMR588A| Fact Market Research

Report Highlights

Atherosclerosis Drugs Market - Scope of the Report

The study on the atherosclerosis drugs market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that are driving the growth of the market. This exclusive study provides incisive insights regarding recent developments in the atherosclerosis drugs market, by analysing the historical data for the period of 2017-2019, and the duration of 2020-2027 that is considered as the forecast period.

Evaluation of the atherosclerosis drugs market’s revenue has been carried out in terms of value (US$ Mn). This research provides information into the key trends that are potential enough to influence the growth of the atherosclerosis drugs market. Besides this, the study also includes several macroeconomic and microeconomic growth indicators complementing the growth of the atherosclerosis drugs market during the forecast period. This detailed study provides information into key dynamics, and their influence on the atherosclerosis drugs market during the forecast period.

The report also provides information about the key challenges and threats that could deter the growth potential of players in the atherosclerosis drugs market. The study unveils profitable opportunities for manufacturers, which they can adopt to strengthen their position in the global atherosclerosis drugs market. With a view of aiding stakeholders in the atherosclerosis drugs market, the study comprises a detailed section on the competition analysis.

This exclusive study offers a dashboard view of the atherosclerosis drugs market, with detailed information about market players, based on overall revenue, key developments, and their market presence. Additionally, key strategies of players in the atherosclerosis drugs market have also been included in this comprehensive study.

Revenue of the atherosclerosis drugs market has been evaluated in terms of US$ Mn for the period of 2020 to 2027. In addition to this, compound annual growth rate has been calculated for all key segments for the forecast period of 2020-2027, considering 2019 as the base year.

Authors of this exclusive study on the atherosclerosis drugs market have analysed key players, based on their financials, products, and strategies, in order to provide key detailed information into the competitive landscape. Key players operating in the atherosclerosis drugs market include Pfizer Inc., GlaxoSmithKline PLC, Amgen Inc., Sanofi, Mylan N.V., F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Bayer AG, Merck & Co., Inc., and Novartis AG.

This exclusive study is produced to offer a detailed perspective of the atherosclerosis drugs market to stakeholders, who include companies and intermediaries engaged in the development, manufacturing, and commercialisation of drugs. The report is also aimed at offering crucial information about the atherosclerosis drugs market to new players.

Atherosclerosis Drugs Market - Research Methodology

The primary objective of this exclusive study on the atherosclerosis drugs market is to offer precise estimates and forecasts of the market in terms of value (US$ Mn) for the period of 2020-2027. The secondary objective includes analysis of key market segments exhibiting significant growth rates, leading strategies adopted by players in the atherosclerosis drugs market, and the adoption rate of atherosclerosis drugs in key regions across the world.

  • Table 1 : Atherosclerosis Pipeline Analysis
  • Table 2 : Atherosclerosis Pipeline Analysis
  • Table 3 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027
  • Table 4 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027
  • Table 5 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Region, 2020–2027
  • Table 6 : North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class 2020–2027
  • Table 7 : North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027
  • Table 8 : North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country, 2020–2027
  • Table 9 : Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027
  • Table 10 : Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027
  • Table 11 : Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2020–2027
  • Table 12 : Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027
  • Table 13 : Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027
  • Table 14 : Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2020–2027
  • Table 15 : Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class 2020–2027
  • Table 16 : Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027
  • Table 17 : Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country / Sub-region, 2020–2027
  • Table 18 : Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2020–2027
  • Table 19 : Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2020–2027
  • Table 20 : Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2020–2027
  • Figure 1 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) and Distribution (%), by Region, 2019 and 2027
  • Figure 2 : Global Atherosclerosis Drugs Market Revenue (US$ Mn), by Drug Class, 2019
  • Figure 3 : Global Atherosclerosis Drugs Market Revenue Share Analysis, by Drug Class, 2019
  • Figure 4 : Market Overview
  • Figure 5 : Global Atherosclerosis Drugs Market Revenue Share, by Drug Class, 2019
  • Figure 6 : Global Atherosclerosis Drugs Market Revenue Share, by Distribution Channel, 2019
  • Figure 7 : Global Atherosclerosis Drugs Market Revenue Share, by Region, 2019
  • Figure 8 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, 2020–2027
  • Figure 9 : Global Atherosclerosis Drugs Market Revenue Share Analysis, by Drug Class, 2019 and 2027
  • Figure 10 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-platelet Medications, 2020–2027
  • Figure 11 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholesterol Lowering Medications, 2020–2027
  • Figure 12 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fibric Acid and Omega-3 Fatty Acid Derivatives, 2020–2027
  • Figure 13 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Beta Blockers, 2020–2027
  • Figure 14 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Angiotensin-converting Enzyme (ACE) Inhibitors, 2020–2027
  • Figure 15 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Calcium Channel Blockers, 2020–2027
  • Figure 16 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Diuretics, 2020–2027
  • Figure 17 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2020–2027
  • Figure 18 : Global Atherosclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
  • Figure 19 : Global Atherosclerosis Drugs Market Revenue Share Analysis, by Distribution Channel, 2019 and 2027
  • Figure 20 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth(%) Projection, by Retail Pharmacies, 2020–2027
  • Figure 21 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2020–2027
  • Figure 22 : Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2020–2027
  • Figure 23 : Global Atherosclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027
  • Figure 24 : Global Atherosclerosis Drugs Market Revenue Share Analysis, by Region, 2019 and 2027
  • Figure 25 : Global Atherosclerosis Drugs Market Attractiveness Analysis, by Region, 2019–2027
  • Figure 26 : North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2027
  • Figure 27 : North America Atherosclerosis Drugs Market Revenue Share Analysis, by Drug Class, 2019 and 2027
  • Figure 28 : North America Atherosclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
  • Figure 29 : North America Atherosclerosis Drugs Market Revenue Share Analysis, by Distribution Channel, 2019 and 2027
  • Figure 30 : North America Atherosclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
  • Figure 31 : North America Atherosclerosis Drugs Market Revenue Share Analysis, by Country/Sub-region, 2019 and 2027
  • Figure 32 : North America Atherosclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
  • Figure 33 : Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2027
  • Figure 34 : Europe Atherosclerosis Drugs Market Revenue Share Analysis, by Drug Class, 2019 and 2027
  • Figure 35 : Europe Atherosclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
  • Figure 36 : Europe Atherosclerosis Drugs Market Revenue Share Analysis, by Distribution Channel, 2019 and 2027
  • Figure 37 : Europe Atherosclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027
  • Figure 38 : Europe Atherosclerosis Drugs Market Revenue Share Analysis, by Country/Sub-region, 2019 and 2027
  • Figure 39 : Europe Atherosclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
  • Figure 40 : Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2027
  • Figure 41 : Asia Pacific Atherosclerosis Drugs Market Revenue Share Analysis, by Drug Class, 2019 and 2027
  • Figure 42 : Asia Pacific Atherosclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
  • Figure 43 : Asia Pacific Atherosclerosis Drugs Market Revenue Share Analysis, by Distribution Channel, 2019 and 2027
  • Figure 44 : Asia Pacific Atherosclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
  • Figure 45 : Asia Pacific Atherosclerosis Drugs Market Revenue Share Analysis, by Country/Sub-region, 2019 and 2027
  • Figure 46 : Asia Pacific Atherosclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
  • Figure 47 : Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2027
  • Figure 48 : Latin America Atherosclerosis Drugs Market Revenue Share Analysis, by Drug Class, 2019 and 2027
  • Figure 49 : Latin America Atherosclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
  • Figure 50 : Latin America Atherosclerosis Drugs Market Revenue Share Analysis, by Distribution Channel, 2019 and 2027
  • Figure 51 : Latin America Atherosclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
  • Figure 52 : Latin America Atherosclerosis Drugs Market Revenue Share Analysis, by Country/Sub-region, 2019 and 2027
  • Figure 53 : Latin America Atherosclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
  • Figure 54 : Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2027
  • Figure 55 : Middle East & Africa Atherosclerosis Drugs Market Revenue Share Analysis, by Drug Class, 2019 and 2027
  • Figure 56 : Middle East & Africa Atherosclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027
  • Figure 57 : Middle East & Africa Atherosclerosis Drugs Market Revenue Share Analysis, by Distribution Channel, 2019 and 2027
  • Figure 58 : Middle East & Africa Atherosclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
  • Figure 59 : Middle East & Africa Atherosclerosis Drugs Market Revenue Share Analysis, by Country/Sub-region, 2019 and 2027
  • Figure 60 : Middle East & Africa Atherosclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
  • Figure 61 : Market Position Analysis, 2019, by Tier and Size of the Company
  • Figure 62 : GlaxoSmithKline plc (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 63 : GlaxoSmithKline plc Breakdown of Net Sales (%), by Region/Country, 2019
  • Figure 64 : GlaxoSmithKline plc Revenue Breakdown of Net Sales (%), by Business segment, 2019
  • Figure 65 : GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 66 : Sanofi (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 67 : GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 68 : Sanofi Revenue Breakdown of Net Sales (%), by Pharmaceutical Business segment, 2019
  • Figure 69 : Sanofi R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019
  • Figure 70 : F. Hoffmann-La Roche Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 71 : F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Region, 2019
  • Figure 72 : F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Pharmaceutical Division, 2019
  • Figure 73 : F. Hoffmann-La Roche Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 74 : Bayer AG, Pharmaceutical Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
  • Figure 75 : Bayer AG Breakdown of Net Sales (%), by Region, 2019
  • Figure 76 : Bayer AG Revenue Breakdown of Net Sales (%), by Business segment, 2019
  • Figure 77 : Bayer AG, pharmaceutical segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 78 : Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 79 : Novartis AG Breakdown of Net Sales (%) of Innovative Medicines Business Segment, by Region/Country, 2019
  • Figure 80 : Novartis AG Revenue Breakdown of Net Sales (%), by Innovative Medicines Segment, 2019
  • Figure 81 : Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 82 : Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 83 : Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2019
  • Figure 84 : Merck & Co., Inc. Revenue Breakdown of Net Sales (%), by Segment, 2019
  • Figure 85 : Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 86 : Johnson & Johnson Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
  • Figure 87 : Johnson & Johnson Breakdown of Net Sales (%), of Pharmaceutical Segment by Region/Country, 2019
  • Figure 88 : Johnson & Johnson Revenue Breakdown of Net Sales (%), by Pharmaceutical Segment, 2019
  • Figure 89 : Johnson & Johnson, Pharmaceutical Segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019
  • Figure 90 : Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 91 : Mylan N.V. R&D Expenses (US$ Mn), 2019–2019
  • Figure 92 : Mylan N.V. Breakdown of Net Sales, by Region, 2019
  • Figure 93 : Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 94 : Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2019
  • Figure 95 : Amgen Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), by Segment 2014–2019
  • Figure 96 : Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2019
  • Figure 97 : Pfizer, Inc. Breakdown of Net Sales, by Geography, 2019
  • Figure 98 : Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2019
  • Figure 99 : Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2019

Fact.MR is an independent, pure play market intelligence firm incorporated with an objective to deliver high quality, customized market research solutions that help our clients successfully go to the market equipped with actionable insights capable of impacting crucial business decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report